Targeting and Cytotoxicity of SapC-DOPS Nanovesicles in Pancreatic Cancer

Only a small number of promising drugs target pancreatic cancer, which is the fourth leading cause of cancer deaths with a 5-year survival of less than 5%. Our goal is to develop a new biotherapeutic agent in which a lysosomal protein (saposin C, SapC) and a phospholipid (dioleoylphosphatidylserine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Zhengtao, Abu-Baker, Shadi, Palascak, Mary B., Ahmad, Syed A., Franco, Robert S., Qi, Xiaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790873/
https://www.ncbi.nlm.nih.gov/pubmed/24124494
http://dx.doi.org/10.1371/journal.pone.0075507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790873/
https://www.ncbi.nlm.nih.gov/pubmed/24124494
http://dx.doi.org/10.1371/journal.pone.0075507

Ejemplares similares